Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis.

K, Kurasawa; S, Arai; Y, Namiki; A, Tanaka; Y, Takamura; T, Owada; M, Arima; R, Maezawa

doi:10.1093/rheumatology/key188

Public

Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis.

Shared by NobleBlocks on Dec 1, 2018 • 12:00 AM UTC

Authors:

Kurasawa K

Arai S

Namiki Y

Abstract

<h4>Objective</h4>We aimed to determine the outcome of combination therapy with tofacitinib (TOF) in a case series of refractory rapidly progressive interstitial lung disease (ILD) associated with anti-melanoma differentiation-associated 5 gene (MDA5) antibody-positive (Ab+) DM. Patients who had poo...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!